Estrogens, homocysteine, vasodilatation and menopause: basic mechanisms, interactions and clinical implications.
Estrogens influence the independent cardiovascular risk factor homocysteine as well as vasodilatation. Homocysteine alone also influences vasodilatation, indicating a relational triangle that seems important in interpreting the isolated effects of estrogens on homocysteine metabolism and vasoreactivity. This paper gives an overview of the current understanding regarding vasoreactivity, homocysteine metabolism and the role of estrogens. This is placed against the background of the clinical trials on the effect of postmenopausal hormone replacement therapy on homocysteine levels and addresses the importance of the interaction between homocysteine, estrogens and vasoreactivity.
D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000502:physiology*; D005260:Female; D006710:Homocysteine / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D017698:Postmenopause / Q000502:physiology*; D014664:Vasodilation / Q000502:physiology*
D004967:Estrogens; D006710:Homocysteine